ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 109 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $871,808 | -53.3% | 43,460 | -34.4% | 0.00% | -40.0% |
| Q2 2023 | $1,867,728 | +35.8% | 66,208 | -17.2% | 0.01% | +25.0% |
| Q1 2023 | $1,375,364 | -12.4% | 79,963 | +2.5% | 0.00% | -20.0% |
| Q4 2022 | $1,570,618 | +57.7% | 77,985 | +69.6% | 0.01% | +66.7% |
| Q3 2022 | $996,000 | -27.8% | 45,986 | -6.3% | 0.00% | -25.0% |
| Q2 2022 | $1,379,000 | -37.7% | 49,071 | +2.2% | 0.00% | -20.0% |
| Q1 2022 | $2,215,000 | -49.9% | 48,000 | -8.7% | 0.01% | -44.4% |
| Q4 2021 | $4,422,000 | +51.5% | 52,600 | +20.1% | 0.01% | +50.0% |
| Q3 2021 | $2,919,000 | +41.8% | 43,800 | +13.2% | 0.01% | +50.0% |
| Q2 2021 | $2,059,000 | +22.6% | 38,700 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $1,679,000 | -19.2% | 38,700 | -3.2% | 0.00% | -20.0% |
| Q4 2020 | $2,078,000 | +285.5% | 40,000 | +142.4% | 0.01% | +400.0% |
| Q3 2020 | $539,000 | -31.9% | 16,500 | 0.0% | 0.00% | -50.0% |
| Q2 2020 | $792,000 | – | 16,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Decheng Capital Management III (Cayman), LLC | 2,099,583 | $42,117,635 | 14.06% |
| Mayo Clinic | 187,143 | $3,754,089 | 7.23% |
| Matrix Capital Management Company, LP | 13,959,973 | $280,037,058 | 3.36% |
| 5AM Venture Management, LLC | 490,000 | $9,829,400 | 2.83% |
| Eventide Asset Management | 7,814,039 | $156,749,622 | 2.82% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $19,287,410 | 2.70% |
| Avidity Partners Management LP | 2,100,000 | $42,126,000 | 1.70% |
| First Light Asset Management, LLC | 848,477 | $17,020,449 | 1.62% |
| Sofinnova Investments, Inc. | 1,211,641 | $24,305,518 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 386,525 | $7,753,692 | 1.51% |